Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum WS Bimatoprost (ausschl. in der Wirkstärke 0,1mg/ml), ATC S01EE03 f. d. Z. 01.6.26-31.5.28 (zzgl. V.-Option 1x12 Mon)

Section 130a(8) SGB V allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the awarding of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For pharmaceuticals to be specified by the bidder in Appendix 2 to the contract for the aforementioned substance Bimatoprost (exclusively in the strength 0.1 mg/ml), ATC S01EE03, DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the aforementioned substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028 (plus extension option 1x12 months). It will automatically end, regardless of this, with the entry into force of the exclusive contract.